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In the ubiquitin proteasome system, the E3 ligase
SCF-Skp2 and its accessory protein, Cks1, promote
proliferation largely by inducing the degradation of
the CDK inhibitor p27. Overexpression of Skp2 in
human cancers correlates with poor prognosis, and
deregulation of SCF-Skp2-Cks1 promotes tumori-
genesis in animal models. We identified small mole-
cule inhibitors specific to SCF-Skp2 activity using
in silico screens targeted to the binding interface for
p27. These compounds selectively inhibited Skp2-
mediated p27 degradation by reducing p27 binding
through key compound-receptor contacts. In cancer
cells, the compounds induced p27 accumulation in
a Skp2-dependent manner and promoted cell-type-
specific blocks in the G1 or G2/M phases. Designing
SCF-Skp2-specific inhibitorsmay be a novel strategy
to treat cancers dependent on the Skp2-p27 axis.
INTRODUCTION
The ubiquitin proteasome system (UPS) is essential for the turn-
over of almost all cellular proteins, maintaining homeostatic
levels in normal cells while controlling levels of oncogenes and
tumor suppressors in transformed cells. In an ATP-dependent
process, ubiquitin is transferred from the ubiquitin-activating
enzyme (E1) to the ubiquitin-conjugating enzyme (E2) and cova-
lently attached via an isopeptide linkage to a target protein
bound to an ubiquitin ligase (E3) (Ciechanover, 2005). Chains
of four or more ubiquitin domains trigger degradation by the
26S proteasome.
Food and Drug Administration approval of the proteasome
inhibitor Bortezomib (Velcade, Millennium Pharmaceuticals)
established the UPS as a validated target for treatment of
multiple myeloma and mantle cell lymphoma (Bross et al.,
2004; Kane et al., 2007). However, advances in the clinical use
of Bortezomib for solid tumors are lacking, resistance is devel-
oping, and peripheral neuropathy is a major side effect (Argyriou
et al., 2008; Orlowski and Kuhn, 2008). Recent investigations are
now focused on inhibiting UPS targets upstream of the protea-
some (Ceccarelli et al., 2011; Orlicky et al., 2010; Soucy et al.,Chemistry & Biology 19, 1515–1522009). Of particular interest are inhibitors specific to E3 ligases
in the hope of reducing off-target effects (Sun, 2006).
The Skp1-Cullin1-F-box (SCF) family is a multiprotein RING-
finger E3 ligase that drives each stage of the cell cycle by con-
trolling the protein levels of cyclins and cyclin-dependent kinase
inhibitors (CKIs) (Cardozo and Pagano, 2004). Through a coordi-
nated repertoire of protein-protein interactions, the scaffold
protein Cullin-1 (Cul1) binds both the Ring-box protein 1
(Rbx1), recruiting the E2-ubiquitin complex, and the adaptor
protein Skp1, recruiting the F-Box E3 ligase (Petroski and
Deshaies, 2005). The F-box family members dictate the sub-
strate by binding a degron that is usually, but not always, post-
translationally modified (Skowyra et al., 1997).
The F-box protein Skp2 (S-phase kinase-associated protein 2)
is overexpressed in human cancers and implicated in multiple
murine cancer models (Frescas and Pagano, 2008; Lin et al.,
2010; Nakayama and Nakayama, 2006). SCF-Skp2 degrades
known tumor suppressors CKIs p27, p21, and p57 (Carrano
et al., 1999; Kamura et al., 2003; Yu et al., 1998). Recognition
of the p27 degron is unique, being bound by a complex con-
sisting of Skp2 and an accessory protein, Cdc kinase subunit 1
(Cks1), after phosphorylation on Thr-187 by CyclinE-CDK2
(Ganoth et al., 2001; Montagnoli et al., 1999; Tsvetkov et al.,
1999). Additional nonphosphorylated residues of the p27 degron
reinforce this trimeric complex for a high rate of p27 ubiquityla-
tion (Hao et al., 2005; Sitry et al., 2002;Wang et al., 2003, 2004a).
Small molecule inhibitors have been successfully developed
against other E3 ligase-substrate interfaces, including Mdm2-
p53 and IAPs-caspases (Vassilev et al., 2004; Wang et al.,
2004b). High-throughput screens designed to detect small mole-
cules that stabilize p27 identified compounds that either
inhibited 26S proteasome activity, prevented Skp2 from incor-
porating into the SCF complex, or downregulated Skp2 mRNA
(Chen et al., 2008; Nickeleit et al., 2008; Rico-Bautista et al.,
2010). No inhibitors specifically and directly targeted to the E3
ligase activity of Skp2 have been identified, however.
We hypothesized that such inhibitors could be identified
using structure-based drug discovery to target specific three-
dimensional (3D) molecular surfaces, or pockets, at the sub-
strate’s binding site (Cardozo and Abagyan, 2005; Cardozo and
Pagano, 2007). Our laboratory previously identified what, to our
knowledge, are the first reported selective inhibitors against
PERK catalytic activity using a pocket-targeted approach
(Wang et al., 2010). In the present study, we adapted this4, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1515
Figure 1. In Silico and In Vitro Screens for
Skp2 Ligase Inhibitors
(A, Top) ICM 3D receptor model of Skp2 (gold
ribbon), Cks1 (green ribbon), and p27 phospho-
peptide (purple ribbon, phospho-T187 and E185 in
ball and stick). Key residues important for E185
interactions are highlighted in wire. (Bottom) Blue
pocket exposed with removal of p27 peptide and
antagonizes p27-E185 interactions.
(B) Calibration of the in vitro ubiquitylation assay.
Immunoblotting for p27 polyubiquitylation [ladder,
p27-(Ub)n], Cks1, Cyclin E, Cul1, Skp2, and Skp1
levels in the absence of vehicle, Cks1, or CyclinE/
CDK2; or in the presence of vehicle (0.1% DMSO),
1 mM NEDD8-activating enzyme inhibitor MLN-
4924, or 50 mM CDK2 inhibitor Roscovitine.
(C) Representative primary screen for activity.
Immunoblotting for p27-(Ub)n, Cul1, Skp2, and
Skp1 in ubiquitylation assays treated with vehicle
(0.1% DMSO) or 50 mM inhibitor (C1, C2, C20,
or C16).
(D) E2 charging unaffected by active compound.
Immunoblotting for His-tagged Ubc3-ubiquitin
conjugates (Ubc3Ub) in the presence of vehicle
(0.1% DMSO; Veh) or 50 mM inhibitor (C1, C2,
C20, or C16) under nonreducing or reducing
(b-mercaptoethanol; BME) conditions.
(E) Compound treatment blocks the physical
p27-Skp2 interaction. Immunoblotting for p27,
Skp2, and Skp1 from HA-immunoprecipitates of
ubiquitylation assays treated with vehicle (0.1%
DMSO, Veh) or 50 mM C1. No background using
rabbit reticulocyte lysate (RRL) only.
See also Figure S1.
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SCF-Skp2 E3 Ligase Inhibitorsapproach to target a protein-protein interface with an in silico
structure-based discovery tool, virtual ligand screening (VLS),
against a pocket identified at the p27-binding interface formed
by Skp2-Cks1. The combination of VLS, chemical similarity
searches, in vitro functional screens, and counterscreens identi-
fied four selective inhibitors of Skp2 ligase activity. The inhibitors
increased both p27 protein level and half-life in metastatic mela-
noma cell lines, with this activity dependent on Skp2. Inhibitor
treatments in various cancer cells also shifted the population of
cells into G1, or G2/M phase, and this phenotype was both p27
and cell type dependent.
RESULTS
Identification of Small Molecule Inhibitors
The published Skp2-Cks1-p27 crystal structure (Figure 1A, top)
was interrogated with ICM-PocketFinder (Molsoft, La Jolla, CA,1516 Chemistry & Biology 19, 1515–1524, December 21, 2012 ª2012 Elsevier Ltd All rights reUSA) to identify a pocket (blue geometric
object) formed jointly by Skp2 and Cks1
(Figure 1A, bottom) and flanked by resi-
dues Skp2-R294, Skp2-Y346, Cks1-
R44, and Cks1-Q52, which are essential
for p27 binding and/or ubiquitylation
(Hao et al., 2005; Sitry et al., 2002; Unger-
mannova et al., 2005; Wang et al., 2004a).
The pocket’s area and volume fall withina range calculated to be permissive for druglike small molecule
binding (Anet al., 2004;CardozoandAbagyan,2005). Thispocket
was targeted in a virtual screen (ICM-VLS) of 315,000 diverse
compounds (ChemBridge, La Jolla, CA, USA), and, from the
202 VLS hits, 96 compounds were selected based on calculated
binding score and Lipinski properties (Lipinski et al., 2001).
The 96 hits were tested in an in vitro ubiquitylation assay driven
by in-vitro-transcribed/translated Skp2, Cks1, and p27 (Sitry
et al., 2002). Assay sensitivity was established for various criteria
(Figure 1B): enhanced ubiquitylation with Cks1 (lane 2), kinase
activity requirement (lane 3), and responsiveness to known inhib-
itors of Cullin (lane 5) or Cdk2 (lane 6) activity (Meijer et al., 1997;
Soucy et al., 2009). Compounds showing at least 50% inhibition
of Skp2-mediated p27 ubiquitylation (Figure 1C; data not shown)
were counterscreened for inactivity against two antitarget E3
ligases: MDM2 and SCF-bTrCP (Figures S1A and S1B available
online). Compounds C1 and C2 were identified from the primaryserved
Figure 2. Structure-Function Approach to
Identify Key Contacts
(A) Chemical structure of C1 and C2. Red box,
active group used as query in chemical similarity
search.
(B) Predicted conformationswith lowest energy for
C1 and C2 (ball and stick) interacting with residues
(wire) in Skp2 (gold ribbon) and Cks1 (green
ribbon). Hydrogen bonds depicted as small balls.
(C) Chemical structure of C16 and C20 with active
groups (red box) shown in (A).
(D) Removal of active groups reverses activity.
Immunoblotting for p27, Skp2, and Skp1 from
ubiquitylation assays treated with vehicle (0.1%
DMSO), 50 mM inhibitors (C2, C20, C1, or C16),
or 50 mM unmatched compound (UM; see Fig-
ure S3A) lacking active groups.
(E) Cks1 mutation reverses inhibitor activity, as
predicted by binding model. Immunoblotting for
p27, Cks1, Skp2, and Skp1 from ubiquitylation
assays using wild-type-Cks1 (left) or Q52L-Cks1
(right) treated with vehicle (0.1% DMSO) or 50 mM
inhibitor (C1 or C16).
See also Figures S2 and S3.
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SCF-Skp2 E3 Ligase InhibitorsVLS and C16 and C20 were identified from a second VLS
(Figure 2).
Secondary bioassays confirmed the selectivity for Skp2-
Cks1 interface by testing compound effects on ubiquitin trans-
fer to either E2-Ubc3 or E2-Ubc5, as observed when ATP or E1
is omitted (Figure 1D; data not shown); level of CyclinE/CDK2
phosphorylation of p27 (Figure S1C); and dose-dependent
inhibition of Skp2 ligase activity (Figure S1D). In addition, C1
reduced the amount of p27, but not Skp1, interacting with
Skp2 (Figure 1E) to a level similar of p27 bound in the absence
of Cks1 (lane 1 versus lane 3), suggesting that inhibitor activity
is dependent on Cks1. Taken together, our approach identified
a set of inhibitors that fit into a molecular surface pocket at the
Skp2-Cks1 interface and block p27 ubiquitylation in vitro but
do not block the non-Skp2-p27 interfaces of the active SCF.
Identification of Contacts Responsible for Inhibitor
Activity
In order to identify the chemical groups responsible for inhibitor
activity, divergent compounds sharing a common R-group withChemistry & Biology 19, 1515–1524, December 21, 2012 ªC1 or C2 (Figure 2A, highlighted in box)
were selected from the PubChem data-
base and docked in silico to the pocket
at the Skp2-Cks1 interface. Compounds
were tested in vitro if they preferentially
docked in positions similar to C1 or
C2 (Figure 2B): either forming predicted
electrostatic interactions with Q52-Cks1
and/or hydrogen bonding to R44-Cks1
or R344-Skp2 (as in C1) or predicted
cation-p interaction with R294-Skp2
and/or a hydrogen bond to R44-Cks1
(as in C2). C16 and C20 were identified
using this method (Figure 2C) and
showed similar inhibition asC1 or C2 (Fig-ure 2D, lane 2 versus 5, lane 7 versus 9) and parallel docking
poses (Figure S2A; data not shown).
To test the necessity of the predicted chemical contact group,
compounds sharing the same scaffold but differing in the key
R-group listed earlier (unmatched compounds; UM) were identi-
fied for each of the four active compounds (Figure S3A). With
loss of the specific contact R-group, levels of p27 ubiquitylation
were restored to vehicle control levels (Figure 2D, lane 1 versus
lanes 4, 6, 8, and 10). Notably, UM-C2a (unmatched compound
for C2) partially reduced p27 ubiquitylation (Figure 2D, lane 1
versus lane 3), suggesting that both the distance and charge of
the contact group is important for C2 activity. Compound C1
contains a potentially promiscuous rhodanine core, but this
core chemical group was not sufficient to inhibit ubiquitylation
(Figure S3B; data not shown). Thus, chemical fingerprints guided
the identification of additional Skp2 ligase inhibitors, with key 3D
structural chemical groups confirmed necessary for inhibiting
p27 ubiquitylation.
To interrogate the compound-contacting residues on the
Skp2-Cks1 interface, mutants of Skp2 and Cks1 were designed2012 Elsevier Ltd All rights reserved 1517
Figure 3. Binding of Inhibitors Disrupts the
Skp2-p27 Interaction
(A) Reduced ubiquitylation correlates with re-
duced interaction. (Left) Immunoblotting for p27,
Skp2, and Skp1 from ubiquitylation assays treated
with vehicle (0.1% DMSO) or 10 mM inhibitor (C20,
C2, C1, or C16). (Right) Immunoblotting for p27,
Skp1, Cul1, and HA-Skp2 in HA immunopre-
cipitates from ubiquitylation reactions.
(B) Inhibitors reduce p27 binding to Skp2. HA-
Skp2 andCks1 were pretreatedwith vehicle (0.1%
DMSO) or 10 mM inhibitor (C20, C2, C1, or C16)
before added to p27-pT187. HA immunopre-
cipitates were immunoblotted for p27, Cks1,
and Skp2.
(C) Loss of chemically active groups restores
p27 binding. HA-Skp2/Cks1 was pretreated with
10 mM inhibitor (C1 or C2) or corresponding
unmatched compound (UM-C1 or UM-C2b; see
Figure S3A) before p27-pT187 addition. HA
immunoprecipitates were immunoblotted for p27,
Skp1, and Skp2.
(D) Loss of active groups removes compound
binding. Melting temperature (Tm) of recombinant
His-6Skp1-Skp2-Cks1 (1.5 mM) preincubated with
C1 (75 mM), UM-C1 (75 mM), or vehicle (0.5%
DMSO) determined from melting peaks using
differential scanning fluorimetry.
See also Figure S3.
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SCF-Skp2 E3 Ligase Inhibitorsbased on the in silico dockings. The predicted electrostatic inter-
actions between the positive charge on the NH2 side group in
Q52-Cks1 with the COOH-group in C1 and C16 should be lost
when mutated to a neutral-charge leucine (Figure S2B). In vitro
ubiquitylation assays confirm that C1 and C16 are active against
Wild-Type-Cks1 but are inactive against the Q52L-Cks1 mutant
(Figure 2E). In contrast, C2 and C20 strongly inhibited the activity
of both the wild-type Cks1 and the Q52L-Cks1 mutant (data not
shown). This confirms that the Q52-Cks1 residue is important for
only C1 and C16 activity, as predicted by the in silico dockings.
Notably, the basal level of ubiquitylation for the Q52L-Cks1
mutant is reduced (Figure 2E, lane 1 versus lane 5), being the first
report that Q52 contributes partially to p27 degradation. The
R294A-Skp2 and the R44A/H-Cks1 mutants lacked ubiquityla-
tion activity (Figure S2C), preventing the interrogation of these
residues’ contribution to the activity of C2 and C20. R294A-1518 Chemistry & Biology 19, 1515–1524, December 21, 2012 ª2012 Elsevier Ltd All rights reSkp2 was previously shown to reduce
p27 binding, suggesting that the pre-
dicted site for C2 and C20 binding corre-
lates with ligase activity (Ungermannova
et al., 2005). Thus, the predicted 3D
mode of interaction of the compounds
with Skp2-Cks1 was validated at both
the chemical and the protein levels.
Reduction of p27 Binding to Skp2
by the Inhibitors
The docked poses predict that the active
compounds sterically clash with p27 (Fig-
ure S2A). To test this model, immunopre-
cipitations for hemagglutinin (HA)-Skp2were performed from the in vitro ubiquitylation assay mix. The
compounds (10 mM) exhibited various degrees of Skp2 ligase
inhibition (Figure 3A, left), which corresponded with a reduction
of p27 binding to HA-Skp2 (Figure 3A, right). The amount of
Skp1 and Cul1 bound was not affected, confirming that the
compounds are not disrupting SCF formation.
To test if the compounds are specifically targeting the Skp2-
Cks1 interface, immunoprecipitations were performed in the
absence of ubiquitylation. The amount of p27 bound to HA-
Skp2 was reduced in the presence of the inhibitors, whereas
Cks1 binding was unaffected (Figure 3B). Knowing which chem-
ical groups in C1 and C2 are necessary for inhibiting ubiquityla-
tion (Figure 2D; Figure S3A), we tested if the same groups are
responsible for blocking p27 binding. Unmatched compounds
for C1 (UM-C1) and C2 (UM-C2b) lost the ability to inhibit p27
from binding to Skp2 (Figure 3C, lane 3 versus 4, lane 5 versusserved
Figure 4. Inhibitors Induces p27 Protein in
Melanoma Cells
(A) Protein induction following inhibitor treatment.
Immunoblotting for steady-state levels of Skp2
substrates (p27, p21, p130, and Cdt1), Skp2,
Skp1, Cul1, and Nedd8 in 501 Mel cells (left)
treated with vehicle (0.1% DMSO; Veh) or 10 mM
inhibitor (C20, C2, C1, or C16) and (right) untreated
(Unt) or treated with 10 mM proteasome inhibitor
MG-132 (MG) or 400 nM NAE inhibitor MLN-4924
(MLN). Loading normalized to a-tubulin.
(B) Immunoblotting for p27, Skp1, and Skp2
steady-state levels in melanoma cell lines SK-
MEL-147 (top) or SK-MEL-173 (bottom) treated
with vehicle (0.1% DMSO) or 10 mM inhibitor (C20,
C2, C1, or C16). Loading normalized to a-tubulin.
(C) p27 half-life analysis. Cycloheximide half-life
from 501 Mel cells pretreated 16 hr with vehicle
(0.1% DMSO) or 10 mM inhibitor (C16, C1, C20, or
C2). Representative immunoblots at Times 0, 1, 3,
and 5 hr postcycloheximide (n = 3). Total protein
normalized to a-tubulin. Graph shows densitom-
etry levels for percent p27 protein remaining.
(D) p27 induction by compounds is dependent on
Skp2. Immunoblotting for p27 and Skp2 in 501Mel
cells expressing shRNA against Skp2 (shSkp2) or
empty vector (shEmpty) treated with vehicle (0.1%
DMSO; Veh) or 10 mM inhibitor (C1, C2 [left], C16,
or C20 [right]). Loading normalized to a-tubulin.
See also Figure S4.
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SCF-Skp2 E3 Ligase Inhibitorslane 6). The same chemical contact was also important in medi-
ating direct interaction with purified Skp2-Cks1 complex. Using
differential scanning fluorimetry, C1 but not UM-C1 shifted the
melting temperature of Skp2-Cks1 protein complex (Figure 3D).
Surface plasmon resonance assays also confirmed the ability of
the compounds to bind Skp2-Cks1 complex (Figure S3C; data
not shown). These data validate that the specific chemical
groups identified from the VLS docking poses are mediating
the compounds interaction at the Skp2-Cks1 interface and
blocking p27 binding.
Induction of p27 by Inhibitors in Cancer Cells
To test if these compounds prevent p27 degradation in cells, the
metastatic melanoma cell lines 501 Mel, SK-MEL-147, and SK-
MEL-173 were treated with each inhibitor (10 mM) or 0.1%
dimethyl sulfoxide (DMSO) (vehicle). Steady-state protein levels
of p27 were induced with inhibitors in a dose-dependent manner
(Figures 4A and 4B; Figure S4A). p21 protein levels alsoChemistry & Biology 19, 1515–1524, December 21, 2012 ªincreased, supporting the role of Cks1 in
SCF-Skp2-mediated p21 ubiquitylation
(Bornstein et al., 2003). Inhibitor treatment
did not alter protein levels of Skp2, Skp1,
Cul1, and other Skp2 (Cks1-independent)
targets p130, Cdt1, Tob1, and Cyclin E
(Figure 4A left; data not shown). 501 Mel
cells were also treated with MG-132
(a proteasome inhibitor) or MLN-4924
(the NEDD8-activating enzyme inhibitor)
to confirm that p27 and p21 induction
were responsive to known UPS inhibitors(Figure 4A, right). MLN-4924 inhibited neddylation of Cul1, an
effect not mediated by the ligase inhibitors. Thus, treatment of
cells with inhibitors targeting the Skp2-Cks1 interface induces
protein levels of specific Skp2-Cks1 substrates.
To assess the mechanism of p27 induction, cycloheximide
half-lives were analyzed in 501 Mel cell lines pretreated with
each inhibitor (10 mM) or 0.1% DMSO (vehicle). p27 degrades
rapidly with a half-life of 1 hr with vehicle, with this rate slowed
by the inhibitors (Figure 4C). C1 and C2 exhibit the strongest
stabilization, with a p27 half-life greater than 5 hr, whereas C20
extends it to 5 hr and C16 extends it to 3 hr. Protein levels of
Skp2 and Skp1 remained constant (data not shown).
Since p27 has additional reported E3 ligases (Cao et al., 2011;
Kamura et al., 2004), we tested the dependency of inhibitors
for Skp2 using lentiviral tet-inducible short hairpins to Skp2
(shSkp2). Immunoblotting revealed that Skp2 knockdown elimi-
nated inhibitor-mediated p27 induction (Figure 4D, lane 1 versus
lanes 2 and 3), whereas the 501 Mel cells expressing control2012 Elsevier Ltd All rights reserved 1519
Figure 5. Skp2 Ligase Inhibitors Induce Cell
Cycle Changes
(A) p27-dependent G1 arrest. 501 Mel cells ex-
pressing empty vector (shEmpty) or two different
shRNAs (shp27-1 or shp27-5) against p27 were
(left) immunoblotted for p27, Skp2, Skp1, and
a-tubulin or (center) stained with propidium iodide
for fluorescence-activated cell sorting (FACS)
analysis. Graph represents mean ± SD from n = 3.
*p < 0.01; **p < 0.001 compared with shEmpty
(one-way ANOVA followed by Dunnett test).
(Right) shp27-1 501 Mel cells treated with vehicle
(0.1%DMSO; Veh) or 10 mM inhibitor (C1, C16, C2,
or C20) and stained with propidium iodide for
FACS analysis. Graph represents mean ± SD
from n = 4.
(B) G1 induction by inhibitors. shEmpty 501 Mel
cells treated with vehicle (0.1% DMSO; Veh) or
10 mM inhibitor (C1, C16, C2, or C20) were (left)
immunoblotted for p27, Skp2, Skp1, and a-tubulin
or (right) stained with propidium iodide for FACS
analysis. Graph represents mean ± SD from n = 4.
*p < 0.05; **p < 0.01; ***p < 0.001 compared with
shEmpty vehicle (one-way ANOVA followed by
Dunnett test).
(C) G1 or G2/M induction by C1 in breast cancer
cells. (Left) FACS analysis of T47D and MCF-7
treated with vehicle (0.1% DMSO; Veh) or 5 mM
C1. Graph represents mean ± SD from n = 4 for
T47D and n = 3 for MCF-7. *p < 0.0001 compared
with corresponding cell cycle phase in vehicle
(unpaired two-tailed Student’s t test). (Right) FACS
analysis of MCF-7 treated with increasing C1
dose. Graph represents mean ± SD from n = 3.
*p < 0.01; **p < 0.001 compared with vehicle (one-
way ANOVA followed by Dunnett test).
(D) G1 induction by C2 in prostate cancer cells.
FACS analysis of LNCaP cells treated with vehicle
(0.1%DMSO; Veh) or 10 mMC2. Graph represents
mean ± SD from n = 6. *p < 0.0001 compared with
vehicle (unpaired two-tailed Student’s t test).
(E) p27 protein induction in cancer cells. Immu-
noblotting for p27, Skp2, Skp1, and a-tubulin in
MCF-7, T47D, or LNCaP cells treated with vehicle
(0.1% DMSO; Veh), 5 mM Cl, or 10 mM C2.
See also Figure S4.
Chemistry & Biology
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lane 4 versus lanes 5 and 6). Compound-induced p27 levels
were similar to the basal level of p27 in the Skp2 knockdown cells
(Figure 4D, lane 1 versus lanes 5 and 6), suggesting that Skp2 is
responsible for maintaining low levels of p27 in the 501Mel cells.
Taken together, the small molecules targeted to the Skp2-Cks1
interface inhibited Skp2-dependent p27 degradation in meta-
static melanoma cells.
Cell Cycle Effects of Inhibitor Treatment
Skp2 siRNA treatment in melanoma cells results in p27 upregu-
lation and reduced cell growth (Katagiri et al., 2006; Sumimoto
et al., 2006). 501 Mel cells responded to Skp2 ligase inhibitors
by inducing p27 (Figure 4; Figure S4A), with a dose-dependent
effect on cell viability (Figure S4B, left). To address the specific
role of p27 in 501 Mel cell cycle progression, p27 was knock-
down using tet-inducible shRNAs (shp27-1 or shp27-5) and1520 Chemistry & Biology 19, 1515–1524, December 21, 2012 ª2012compared to control empty vector shRNA (shEmpty). FACS
analysis confirmed that the reduction of p27 protein levels
(Figure 5A, left) correlated with a significant decrease in G1
phase cells (p < 0.001) and an increase in S phase cells
(p < 0.01) (Figure 5A, middle). In the cells lacking p27, treatment
with the inhibitors (10 mM for 16 hr) did not alter the cell cycle
profile (Figure 5A, right; data not shown), suggesting that the
inhibitors require p27 to elicit changes in cell cycle. To demon-
strate this, shEmpty control cells were treated with the inhibitors
(10 mM for 16 hr) and showed p27 protein induction (Fig-
ure 5B, left) with a corresponding increase in G1 phase cells
(p < 0.001) and a decrease in S phase cells (p < 0.01 for C1;
p < 0.05 for C16; and p < 0.0001 for C2 and C20) (Figure 5B,
right). Since inhibitor-mediated G1/S arrest is dependent on
p27 and the inhibitors stabilize p27 protein in a Skp2-dependent
manner (Figure 4), the changes observed in the cell cycle most
likely result from the inhibitors targeting Skp2 ligase activity.Elsevier Ltd All rights reserved
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SCF-Skp2 E3 Ligase InhibitorsIn addition to melanomas, the Skp2-p27 axis regulates growth
of breast and prostate cancer cells (Lu et al., 2002; Shibahara
et al., 2005; Sun et al., 2007). Breast cancer cell lines MCF-7
and T47D displayed no significant cellular phenotype after
treatment with C2, C16, and C20 (data not shown). In contrast,
treatment with C1 resulted in a lower rate of proliferating cells
(Figure S4B, right); thus C1 treatment was reduced from 10 mM
to 5 mM in order to monitor early cell cycle effects. T47D cells
treated with C1 (5 mM for 16 hr) displayed an increase in G1
phase (p < 0.0001) and a decrease in S phase (p < 0.0001), corre-
lating with p27 protein induction (Figure 5C, left; Figure 5E,
center). In contrast, MCF-7 cells responded to C1 with a signifi-
cant reduction in G1 phase (35%, p < 0.0001) and an increase in
G2-M phase (43%, p < 0.0001) (Figure 5C left). The G1 reduction
and G2/M arrest are dose dependent on C1 (Figure 5C right;
p < 0.001 and p < 0.01, respectively) and correlate with increased
p27 protein levels (Figure 5E left; Figure S4A, top right). LNCaP
prostate cancer cells treated with C2 (10 mM for 16 hr) displayed
a mild, but significant, increase in G1 cells (p < 0.0001) and
a reduction in S phase cells (p < 0.0001) (Figure 5D), correlating
with p27 protein induction (Figure 5E, right). Therefore, multiple
Skp2 ligase inhibitors induce p27 protein expression in a number
of cancer cells, and this induction correlated with changes in cell
cycle distribution. However, the cell cycle effects are dependent
on cell type, with blocks at either the G1/S transition or in the
G2/M phase.
DISCUSSION
We combined an in silico high-throughput VLS with low-
throughput in vitro bioassays to identify the first set of small
molecule inhibitors targeted to block Skp2-mediated p27 ubiqui-
tylation and alter cell cycle progression.Multiple human cancers,
including prostate, breast, ovarian, lung, and metastatic mela-
noma, express low levels of p27 and high Skp2 protein levels,
with both protein status independently associated with poor
prognosis and low patient survival (Chu et al., 2008; Flørenes
et al., 1998; Hershko, 2008; Li et al., 2004; Woenckhaus et al.,
2005). Thus, the Skp2-p27 axis is an attractive target for drug
discovery, and cancers that rely on Skp2 ligase activity for their
oncogenic properties should be highly susceptible to specific
and direct inhibitors of Skp2-mediated p27 ubiquitylation.
One major challenge we faced was that the target site is a
protein-protein interface. We previously proposed that certain
protein-protein interfaces may be targeted for drug discovery if
they exhibited favorable configurations, including the presence
of a drug-binding pocket of sufficient size located at a function-
ally sensitive location on the interface (Cardozo and Abagyan,
2005). In order to target such surfaces, pocket-specific screen-
ing approaches, as opposed to high-throughput screening
(HTS), must be utilized, of which VLS is perhaps the most
suitable. In this study, we successfully put this theory into prac-
tice. Furthermore, this study extends the theory by suggesting
that pockets formed by the association of two proteins, in this
case, Skp2 and Cks1, are no different from monodomain
pockets and can be equally targeted with success.
A second major challenge was to confirm the primary target of
the inhibitors, given that previous attempts identified com-
pounds that either blocked Skp2 incorporation into an activeChemistry & Biology 19, 1515–152SCF or reduced Skp2 mRNA levels (Chen et al., 2008; Rico-
Bautista et al., 2010). Since our in silico screen selects small
molecules that are highly structurally compatible with the
Skp2-Cks1 protein interface, there is a high likelihood that
validated compounds would not nonspecifically inhibit any of
the multiple proteins/enzymes present in the ubiquitylation
process. This included sites that other small molecules inhibit:
(1) the F-box domain interface with Skp1, (2) CyclinE/Cdk2
kinase activity, (3) E2 Ubc3 (Cdc34) activity, and (4) a known
druggable protein interface MDM2-p53 (Aghajan et al., 2010;
Ceccarelli et al., 2011; Meijer et al., 1997; Millard et al., 2011).
Our compounds do not exhibit activity against any of these off-
targets, showing high selectivity for SCF-Skp2 ligase.
One major advantage of our approach is that the predicted
VLS docking poses highlight key chemical groups that can be
used as a chemical fingerprint to identify additional Skp2 ligase
inhibitors. Interrogating receptor-ligand atomic contacts and
using chemical similarity searches identify more diverse and/or
potent inhibitors (Cheltsov et al., 2010; Wang et al., 2010).
Thus, a blueprint or pharmacophore of the entire Skp2 ligase
inhibitor class is preliminary visualized, which may guide the
rational synthesis of derivatives of C1, C2, C16, and C20 during
future preclinical lead optimization stages. Using thermal shifts
and SPR technologies, the compounds display specific binding
to the Skp2-Cks1 protein complex, but we have not been able to
obtain the cocrystal structures of Skp1-Skp2-Cks1 in complex
with the inhibitors (data not shown), possibly due to stringent
crystallization conditions. Nevertheless, the compendium of
data on these inhibitors leaves little doubt that they act at the
targeted pocket formed by Skp2-Cks1.
By targeting the Skp2-Cks1-p27 interface, we focused on
inhibiting cell cycle progression (Bloom and Pagano, 2003).
Inhibitor-treated metastatic melanoma cells displayed a sig-
nificant shift of cells from S phase into G1 phase that was
dependent on both p27 and Skp2, validating the inhibitors are
regulating p27 levels to elicit cellular changes. It is interesting
that C1 treatment of MCF-7 breast cancer cells lines did not
increase but rather decreased the percentage of cells in G1while
increasing the G2/M population. This sameG2/M phenotype has
been observed in Skp2/MEFs and was reversed by knocking
out p27, suggesting that p27 also plays a pivotal role in G2/M
phase (Nakayama et al., 2004; Pagano, 2004). Elucidation of
the specific mechanismmay now be interrogated in MCF-7 cells
that are especially sensitive to C1-mediated G2/M accumula-
tion. This type of chemical genetic approach would not be
possible without the availability of inhibitors specifically blocking
Skp2-mediated p27 degradation.
In this study, we proved the principle that Skp2 ligase activity
is susceptible to direct inhibition by small molecules. UPS
inhibitor research has accelerated since the FDA approval of
Bortezomib, and the focus has been on the additional enzymes
present in this pathway. Our approach demonstrates that a
nonenzymatic protein-substrate interface is druggable with a
high degree of selectivity. This added level of specificity may
prove indispensable when evaluating combination therapies
between inhibitors of the UPS and conventional chemotherapies
(Ning et al., 2007; Wright, 2010). These pharmacological inhibi-
tors may also aid in identifying and treating cancers that rely
on the Skp2 ligase activity for their oncogenic properties.4, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1521
Chemistry & Biology
SCF-Skp2 E3 Ligase InhibitorsSIGNIFICANCE
Clinical efficacy of the proteasome inhibitor Bortezomib
(Velcade) established the ubiquitin proteasome system
(UPS) as a key target in cancer. In a number of human
cancers, low levels of the cell-cycle regulatory tumor
suppressor p27 correlate with the overexpression of its
UPS E3 ligase SCF-Skp2, suggesting that deregulation of
p27 degradation by the UPS promotes carcinogenesis.
Thus, inhibitors designed to stabilize p27 by selectively
targeting SCF-Skp2 may provide a new avenue of cancer
treatment with enhanced specificity over Bortezomib.
From a chemistry point of view, however, identifying a
specific small molecule inhibitor of the SCF-Skp2/p27 inter-
face is challenging, since this is a protein-protein interface.
Using a structure-based approach encompassing both
in silico virtual ligand screening and in vitro assays, we iden-
tified a diverse set of inhibitors of Skp2-mediated p27 degra-
dation that reduce p27 ubiquitylation by specifically and
competitively inhibiting the Skp2-p27 interaction. In various
cancer cells, these compounds induce p27 and elicit cell
cycle arrest. This work establishes a proof of principle
both for drug discovery targeting Skp2, a potential advance
in biology, and for drug discovery targeted this form of
protein-protein interface, a potential advance in chemistry.
EXPERIMENTAL PROCEDURES
In Silico Assays
The in silico protein receptor and ligand preparations, the docking simulations
during VLS, and the docking score calculations as well as chemical similarity
and substructure searches were carried out with ICM-Pro, ICM-VLS, and
ICM-Chemistry software (Molsoft) (Abagyan et al., 1994). Pockets on the crys-
tallographic structure Protein Data Bank 2ast were identified with the ICM
PocketFinder module in ICM-Pro and screened by ICM-VLS against the
ChemBridge Library (ChemBridge, San Diego, CA, USA) using default ICM-
VLS docking parameters. Dockings used global optimization with a biased
probability Monte Carlo conformational search of fully flexible, full-atom
models of the ligands within a set of grid potential maps calculated from the
coordinates of the atoms in the protein receptor (Abagyan and Totrov, 1994,
2001). These grid energy maps account for the hydrophobic, heavy atom,
and hydrogen van der Waals interactions, hydrogen-bonding interactions,
and electrostatic potential. Hits with VLS docking scores better than 30 U
were further filtered by Lipinski’s rules to eliminate nondruglike compounds.
Substructure searches were performed using the ChemBridge and ICM
MolCart databases, with Tanimoto distance used as a measure of chemical
similarity.
Plasmids
HA-Skp2, Cks1, Q52L-Cks1, p27, Flag-b-TrCP, and HA-PDCD4 cloned
into pcDNA3.1 plasmids were provided by Dr. Michele Pagano (New York
University Medical College [NYUMC]). Short hairpins for p27 (Catalog no.
RHS4740-NM_004064) and Skp2 (Catalog no. RHS4740-NM_005983) in
doxycycline-regulated TRIPZ lentiviral vector were obtained from Open
Biosystems and prepared following manufacturer’s instructions.
Antibodies and Immunoblotting
Antibodies include mouse monoclonal antisera against Skp2/p45 (Invitrogen),
p27 (BD Biosciences), Cks1 (Invitrogen), Cyclin E (Invitrogen), a-tubulin
(Sigma), and HA (Covance); and rabbit polyclonal antisera against phos-
phoThr-187 p27 (Invitrogen), total p27 (Cell Signaling), p21 (Cell Signaling),
Skp1 (Invitrogen), NEDD8 (Cell Signaling), Cul1 (Invitrogen), p130 (Santa
Cruz), Cdt1 (Cell Signaling), His (Santa Cruz), HA (Invitrogen), and b-TrCP
(Invitrogen).1522 Chemistry & Biology 19, 1515–1524, December 21, 2012 ª2012Ubiquitylation Assays
In vitro reconstituted assays were performed as previously described (Dorrello
et al., 2006), with the exceptions of the use of (1) unlabeled proteins (wild-type
and mutant Skp2 and Cks1, p27, Flag-bTrCP, and HA-PDCD4) generated by
in vitro transcription-translation (TNT T7 Coupled Reticulocyte Lysate System,
Promega), (2) chain elongation with nonmethylated ubiquitin, and (3) immuno-
blotting to detect polyubiquitylation. The following reagents were obtained
from Boston Biochem: UBE1, His-UbcH3, His-UbcH5c, Ubiquitin, and Ubiqui-
tin Aldehyde. Additional reagents include CDK2/CyclinE1 (Sigma-Aldrich),
S6K (Invitrogen), okadaic acid (Sigma), and DMSO (Sigma-Aldrich). For
ubiquitin charging, UBE1 (100 nM) and His-UbcH3 (10 ng/ml) were incubated
with ubiquitin (2.5 mg/ml), ATP (2mM), and 10 mMof inhibitors or Vehicle control
for 60 min at 30C. Reactions were stopped in nondenaturing 23 Sample
Buffer, with the addition of 10% b-mercaptoethanol as indicated, and analyzed
by western blotting.
Inhibitors
Control ubiquitylation inhibitors include Roscovitine (Cayman Chemicals),
MG132 (Peptide Institute), and MLN-4924 (Active Biochem). Compounds
obtained from ChemBridge (San Diego, CA, USA) include C1 (6719837), C2
(6544607), and C16 (6744881). C20 (A067/0031209) was obtained from
Ryan Scientific (Mount Pleasant, SC, USA).
Binding and Kinase Assays
In vitro ubiquitylation assays were incubated with anti-HA affinity matrix
(Roche) in immunoprecipitation (IP) buffer (50 mM Tris, pH 7.6, 150 mM
NaCl, 0.1% NP40, and Roche Complete EDTA-free protease tablet) for 16 hr
at 4C. Beads were washed three times with IP buffer and eluted with 23
SDS Sample Buffer (Boston Bioproducts) and 10% b-mercaptoethanol. For
binding without ubiquitylation, HA-Skp2 IVT (10 ml) and Cks1 IVT (10 ml) were
preincubated with anti-HA affinity matrix in IP buffer for 2 hr, with the addition
of p27 kinase reaction (10 ml) for another 16 hr incubation at 4C. All reactions
were analyzed after SDS/PAGE by western blotting. Where indicated, Skp2
and Cks1 were pretreated with 10 mM inhibitors for 30 m. Kinase reactions
were performed with p27 IVT (10 ml) and 0.5 mg/ml CyclinE/CDK2 in kinase
buffer (50 mM Tris HCL, pH 7.5, 10 mM MgCl2, 2 mM ATP, 2.5 mM okadaic
acid, and 0.6 mM dithiothreitol) at 30C for 1 hr.
Differential Scanning Fluorimetry
Protein melt assays were carried out following manufacturer’s protocol on the
LightCycler 480 System II (Roche) using Sypro Orange dye (Sigma). Fluores-
cence (465 nm excitation/580 nm detection) was acquired (10 data points
per second) at a ramp rate of 0.06C/s between 20C and 85C. Melting
temperatures were calculated using the LightCycler 480 Protein Melt analysis
tool (Roche).
Cell Lines and Knockdown
MCF-7 and T47D were purchased from ATCC and cultured as specified.
501 Mel, SK-MEL-147, and SK-MEL-173 were kindly provided by Dr. Eva
Hernando (NYUMC). LNCaP were a kind gift from Dr. Garabedian (NYUMC).
501 Mel were cultured in OPTI-MEM reduced serum supplemented with 5%
fetal bovine serum (FBS) and 1% pen-strep. SK-MEL lines and LNCaP
were cultured in Dulbecco’s modified Eagle’s medium supplemented with
10% FBS and 1% pen-strep. All cell culture reagents were obtained from
GIBCO, except Tet System-approved fetal bovine serum (#631101) and
doxycycline (#631311) supplied by Clontech. For knockdown, 501 Mel cells
were infected with TRIPZ p27, Skp2, or empty vector and treated for
3 days with 2 ng/ml doxycycline. Cells expressing more than 70% red fluores-
cent protein were used for further analysis. From the p27 shRNA set, knock-
down was achieved with V3THS_410220 (shp27-1), and V3THS_372105
(shp27-5). From the Skp2 shRNA set, knockdown was achieved with
V2THS_254607 (shSkp2).
Cell-Based Analysis
Whole-cell extracts were prepared and immunoblotted as previously
described (Dorrello et al., 2006). For knockdown of Skp2 or p27, shRNAs
were induced with 2 ng/ml doxycycline for 48 hr, with the last 16 hr cotreated
with 0.1% Vehicle or 10 mM inhibitors as indicated. For cycloheximide chase,Elsevier Ltd All rights reserved
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20 ng/ml cycloheximide (Sigma) andwhole cell extracts collected for each time
point. Scanning densitometry was performed on immunoblots using Image J
software. For cell cycle analysis, cells were treated with 0.1% Vehicle or
10 mM inhibitors for 16 hr. Cells (1 3 106) were fixed in 70% ethanol for 2 hr,
treated with 200 mg/ml RNase A (Invitrogen) for 30 min, and stained with
20 mg/ml propidium iodine (Sigma). All samples were assayed in triplicates.
Signal was detected using the Becton Dickson LSRII flow cytometer, and
cell cycle profiles were analyzed with FloJo.
Statistical Methodologies
Statistical significance between and among groups was determined by
Student’s paired two-tailed t test or one-way analysis of variance, using
Dunnett’s multiple comparison tests as the post hoc analysis. A p < 0.05
was considered significant (GraphPad Prism Software).
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